Investors expect the company to underperform the broader industry, reflecting in its low P/S ratio. Limited growth rates are anticipated to persist, reducing stock value. If medium-term revenue trends persist, a share price reversal seems unlikely.
Concerns rise for COFCO Biotechnology's financial performance and competitiveness due to decreasing ROCE and sales. Responding to these trends, the stock fell by 11% over five years. Alternatives should be considered unless positive changes occur.
中粮科技股票讨论区
$ALIBABA GROUP HOLDING LTD(BABAF.US)$ $阿里巴巴(BABA.US)$ $中粮科技(000930.SZ)$ $中粮糖业(600737.SH)$ $中粮资本(002423.SZ)$ $恒生科技指数(800700.HK)$
暂无评论